nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—FGFR2—breast cancer	0.206	0.503	CbGaD
Thalidomide—TNF—breast cancer	0.0664	0.162	CbGaD
Thalidomide—PTGS1—breast cancer	0.0552	0.135	CbGaD
Thalidomide—CYP1A1—breast cancer	0.0505	0.123	CbGaD
Thalidomide—CYP1A1—Toremifene—breast cancer	0.0414	0.163	CbGbCtD
Thalidomide—PTGS2—breast cancer	0.0315	0.077	CbGaD
Thalidomide—CYP1A2—Anastrozole—breast cancer	0.0202	0.0798	CbGbCtD
Thalidomide—CYP1A2—Toremifene—breast cancer	0.0185	0.073	CbGbCtD
Thalidomide—CYP2C9—Anastrozole—breast cancer	0.0182	0.0719	CbGbCtD
Thalidomide—CYP3A5—Lapatinib—breast cancer	0.0181	0.0716	CbGbCtD
Thalidomide—CYP1A1—Tamoxifen—breast cancer	0.0151	0.0597	CbGbCtD
Thalidomide—CYP2C19—Lapatinib—breast cancer	0.0146	0.0577	CbGbCtD
Thalidomide—CYP2C9—Idarubicin—breast cancer	0.0138	0.0545	CbGbCtD
Thalidomide—CYP2E1—Tamoxifen—breast cancer	0.0117	0.0461	CbGbCtD
Thalidomide—CYP2E1—Mitoxantrone—breast cancer	0.0114	0.045	CbGbCtD
Thalidomide—CYP3A5—Tamoxifen—breast cancer	0.00908	0.0358	CbGbCtD
Thalidomide—CYP2C9—Capecitabine—breast cancer	0.00757	0.0299	CbGbCtD
Thalidomide—CYP2C19—Tamoxifen—breast cancer	0.00733	0.0289	CbGbCtD
Thalidomide—CYP3A5—Paclitaxel—breast cancer	0.00707	0.0279	CbGbCtD
Thalidomide—CYP3A5—Irinotecan—breast cancer	0.00697	0.0275	CbGbCtD
Thalidomide—CYP1A2—Tamoxifen—breast cancer	0.00676	0.0267	CbGbCtD
Thalidomide—CYP2C9—Tamoxifen—breast cancer	0.00609	0.024	CbGbCtD
Thalidomide—CYP3A5—Docetaxel—breast cancer	0.00511	0.0202	CbGbCtD
Thalidomide—CYP1A2—Fluorouracil—breast cancer	0.00498	0.0197	CbGbCtD
Thalidomide—CYP2C9—Paclitaxel—breast cancer	0.00474	0.0187	CbGbCtD
Thalidomide—CYP2C9—Fluorouracil—breast cancer	0.00449	0.0177	CbGbCtD
Thalidomide—FGFR2—Estradiol—Fulvestrant—breast cancer	0.00211	1	CbGdCrCtD
Thalidomide—Lenalidomide—CDH5—breast cancer	0.00202	0.4	CrCbGaD
Thalidomide—NFKB1—mammary gland—breast cancer	0.00188	0.0496	CbGeAlD
Thalidomide—NFKB1—nipple—breast cancer	0.00156	0.041	CbGeAlD
Thalidomide—FGFR2—mammary gland—breast cancer	0.00141	0.0372	CbGeAlD
Thalidomide—CRBN—nipple—breast cancer	0.00131	0.0344	CbGeAlD
Thalidomide—Lenalidomide—TNFSF11—breast cancer	0.00116	0.23	CrCbGaD
Thalidomide—CRBN—embryo—breast cancer	0.00108	0.0284	CbGeAlD
Thalidomide—FGFR2—embryo—breast cancer	0.000965	0.0254	CbGeAlD
Thalidomide—NFKB1—endometrium—breast cancer	0.00094	0.0248	CbGeAlD
Thalidomide—NFKB1—uterus—breast cancer	0.000866	0.0228	CbGeAlD
Thalidomide—NFKB1—pituitary gland—breast cancer	0.000851	0.0224	CbGeAlD
Thalidomide—NFKB1—adipose tissue—breast cancer	0.000847	0.0223	CbGeAlD
Thalidomide—TNF—lymph node—breast cancer	0.000799	0.021	CbGeAlD
Thalidomide—CRBN—endometrium—breast cancer	0.000788	0.0208	CbGeAlD
Thalidomide—FGFR2—epithelium—breast cancer	0.000787	0.0207	CbGeAlD
Thalidomide—NFKB1—female reproductive system—breast cancer	0.000779	0.0205	CbGeAlD
Thalidomide—NFKB1—adrenal gland—breast cancer	0.00076	0.02	CbGeAlD
Thalidomide—FGFR2—skin of body—breast cancer	0.000749	0.0197	CbGeAlD
Thalidomide—NFKB1—bone marrow—breast cancer	0.000735	0.0194	CbGeAlD
Thalidomide—CRBN—uterus—breast cancer	0.000726	0.0191	CbGeAlD
Thalidomide—CRBN—pituitary gland—breast cancer	0.000713	0.0188	CbGeAlD
Thalidomide—CRBN—adipose tissue—breast cancer	0.00071	0.0187	CbGeAlD
Thalidomide—NFKB1—female gonad—breast cancer	0.000709	0.0187	CbGeAlD
Thalidomide—NFKB1—endocrine gland—breast cancer	0.000659	0.0174	CbGeAlD
Thalidomide—CRBN—female reproductive system—breast cancer	0.000653	0.0172	CbGeAlD
Thalidomide—FGFR2—uterus—breast cancer	0.000651	0.0171	CbGeAlD
Thalidomide—CRBN—adrenal gland—breast cancer	0.000637	0.0168	CbGeAlD
Thalidomide—FGFR2—adipose tissue—breast cancer	0.000636	0.0168	CbGeAlD
Thalidomide—CRBN—bone marrow—breast cancer	0.000616	0.0162	CbGeAlD
Thalidomide—CRBN—female gonad—breast cancer	0.000594	0.0156	CbGeAlD
Thalidomide—FGFR2—female reproductive system—breast cancer	0.000585	0.0154	CbGeAlD
Thalidomide—FGFR2—adrenal gland—breast cancer	0.000571	0.015	CbGeAlD
Thalidomide—CRBN—endocrine gland—breast cancer	0.000552	0.0146	CbGeAlD
Thalidomide—FGFR2—female gonad—breast cancer	0.000532	0.014	CbGeAlD
Thalidomide—FGFR2—endocrine gland—breast cancer	0.000495	0.013	CbGeAlD
Thalidomide—CYP2C9—mammary gland—breast cancer	0.000492	0.013	CbGeAlD
Thalidomide—NFKB1—lymph node—breast cancer	0.000456	0.012	CbGeAlD
Thalidomide—CYP1A2—nipple—breast cancer	0.000429	0.0113	CbGeAlD
Thalidomide—CYP1A1—nipple—breast cancer	0.000423	0.0111	CbGeAlD
Thalidomide—Menadione—NQO2—breast cancer	0.000422	0.0834	CrCbGaD
Thalidomide—CRBN—lymph node—breast cancer	0.000382	0.0101	CbGeAlD
Thalidomide—PTGS1—nipple—breast cancer	0.000372	0.00979	CbGeAlD
Thalidomide—Menadione—BGLAP—breast cancer	0.000305	0.0603	CrCbGaD
Thalidomide—PTGS2—embryo—breast cancer	0.000293	0.00772	CbGeAlD
Thalidomide—CYP1A1—epithelium—breast cancer	0.000285	0.00751	CbGeAlD
Thalidomide—CYP1A1—skin of body—breast cancer	0.000271	0.00714	CbGeAlD
Thalidomide—PTGS1—epithelium—breast cancer	0.00025	0.00659	CbGeAlD
Thalidomide—PTGS2—epithelium—breast cancer	0.000239	0.0063	CbGeAlD
Thalidomide—PTGS1—skin of body—breast cancer	0.000238	0.00627	CbGeAlD
Thalidomide—CYP1A1—uterus—breast cancer	0.000235	0.0062	CbGeAlD
Thalidomide—CYP1A1—adipose tissue—breast cancer	0.00023	0.00607	CbGeAlD
Thalidomide—PTGS2—skin of body—breast cancer	0.000228	0.00599	CbGeAlD
Thalidomide—CYP3A5—adipose tissue—breast cancer	0.000225	0.00593	CbGeAlD
Thalidomide—PTGS1—endometrium—breast cancer	0.000224	0.00591	CbGeAlD
Thalidomide—CYP2C19—endocrine gland—breast cancer	0.000222	0.00586	CbGeAlD
Thalidomide—Pomalidomide—TNF—breast cancer	0.000221	0.0437	CrCbGaD
Thalidomide—PTGS2—endometrium—breast cancer	0.000215	0.00565	CbGeAlD
Thalidomide—CYP1A1—female reproductive system—breast cancer	0.000212	0.00558	CbGeAlD
Thalidomide—PTGS1—uterus—breast cancer	0.000207	0.00545	CbGeAlD
Thalidomide—Menadione—NQO1—breast cancer	0.000206	0.0408	CrCbGaD
Thalidomide—CYP2C9—female reproductive system—breast cancer	0.000204	0.00537	CbGeAlD
Thalidomide—PTGS1—pituitary gland—breast cancer	0.000203	0.00535	CbGeAlD
Thalidomide—PTGS1—adipose tissue—breast cancer	0.000202	0.00533	CbGeAlD
Thalidomide—PTGS2—uterus—breast cancer	0.000198	0.00521	CbGeAlD
Thalidomide—PTGS2—pituitary gland—breast cancer	0.000194	0.00511	CbGeAlD
Thalidomide—PTGS2—adipose tissue—breast cancer	0.000193	0.00509	CbGeAlD
Thalidomide—CYP2E1—female reproductive system—breast cancer	0.000193	0.00509	CbGeAlD
Thalidomide—CYP1A1—female gonad—breast cancer	0.000193	0.00507	CbGeAlD
Thalidomide—CYP2E1—adrenal gland—breast cancer	0.000188	0.00496	CbGeAlD
Thalidomide—CYP3A5—female gonad—breast cancer	0.000188	0.00496	CbGeAlD
Thalidomide—PTGS1—female reproductive system—breast cancer	0.000186	0.0049	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—breast cancer	0.000182	0.00478	CbGeAlD
Thalidomide—PTGS1—adrenal gland—breast cancer	0.000181	0.00478	CbGeAlD
Thalidomide—CYP1A1—endocrine gland—breast cancer	0.000179	0.00472	CbGeAlD
Thalidomide—PTGS2—female reproductive system—breast cancer	0.000178	0.00468	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—breast cancer	0.000175	0.00461	CbGeAlD
Thalidomide—PTGS2—adrenal gland—breast cancer	0.000173	0.00457	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—breast cancer	0.000172	0.00454	CbGeAlD
Thalidomide—PTGS1—female gonad—breast cancer	0.000169	0.00446	CbGeAlD
Thalidomide—PTGS2—bone marrow—breast cancer	0.000168	0.00442	CbGeAlD
Thalidomide—CYP2E1—endocrine gland—breast cancer	0.000163	0.0043	CbGeAlD
Thalidomide—PTGS2—female gonad—breast cancer	0.000162	0.00426	CbGeAlD
Thalidomide—PTGS1—endocrine gland—breast cancer	0.000157	0.00415	CbGeAlD
Thalidomide—PTGS2—endocrine gland—breast cancer	0.00015	0.00396	CbGeAlD
Thalidomide—Menadione—MTHFR—breast cancer	0.000129	0.0254	CrCbGaD
Thalidomide—CYP1A1—lymph node—breast cancer	0.000124	0.00326	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—breast cancer	0.000113	0.0223	CrCbGaD
Thalidomide—PTGS1—lymph node—breast cancer	0.000109	0.00287	CbGeAlD
Thalidomide—Pomalidomide—CYP3A4—breast cancer	0.000107	0.0212	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—breast cancer	0.000105	0.0208	CrCbGaD
Thalidomide—PTGS2—lymph node—breast cancer	0.000104	0.00274	CbGeAlD
Thalidomide—Lenalidomide—ABCB1—breast cancer	9.59e-05	0.019	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—breast cancer	8.92e-05	0.0177	CrCbGaD
Thalidomide—Menadione—CYP1A1—breast cancer	7.71e-05	0.0153	CrCbGaD
Thalidomide—Oedema peripheral—Doxorubicin—breast cancer	1.3e-05	7.78e-05	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—breast cancer	1.3e-05	7.77e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Docetaxel—breast cancer	1.29e-05	7.76e-05	CcSEcCtD
Thalidomide—Dyspnoea—Capecitabine—breast cancer	1.29e-05	7.76e-05	CcSEcCtD
Thalidomide—Fatigue—Docetaxel—breast cancer	1.29e-05	7.75e-05	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—breast cancer	1.29e-05	7.74e-05	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—breast cancer	1.29e-05	7.74e-05	CcSEcCtD
Thalidomide—Nausea—Mitoxantrone—breast cancer	1.29e-05	7.72e-05	CcSEcCtD
Thalidomide—Nausea—Irinotecan—breast cancer	1.29e-05	7.72e-05	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—breast cancer	1.28e-05	7.71e-05	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—breast cancer	1.28e-05	7.69e-05	CcSEcCtD
Thalidomide—Pain—Docetaxel—breast cancer	1.28e-05	7.68e-05	CcSEcCtD
Thalidomide—Constipation—Docetaxel—breast cancer	1.28e-05	7.68e-05	CcSEcCtD
Thalidomide—Back pain—Methotrexate—breast cancer	1.28e-05	7.68e-05	CcSEcCtD
Thalidomide—Dyspepsia—Capecitabine—breast cancer	1.28e-05	7.66e-05	CcSEcCtD
Thalidomide—Chills—Epirubicin—breast cancer	1.28e-05	7.65e-05	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—breast cancer	1.27e-05	7.62e-05	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—breast cancer	1.27e-05	7.61e-05	CcSEcCtD
Thalidomide—Asthenia—Paclitaxel—breast cancer	1.27e-05	7.61e-05	CcSEcCtD
Thalidomide—Decreased appetite—Capecitabine—breast cancer	1.26e-05	7.56e-05	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—breast cancer	1.26e-05	7.54e-05	CcSEcCtD
Thalidomide—Nausea—Gemcitabine—breast cancer	1.25e-05	7.52e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Capecitabine—breast cancer	1.25e-05	7.51e-05	CcSEcCtD
Thalidomide—Fatigue—Capecitabine—breast cancer	1.25e-05	7.5e-05	CcSEcCtD
Thalidomide—Pruritus—Paclitaxel—breast cancer	1.25e-05	7.5e-05	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—breast cancer	1.25e-05	7.48e-05	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—breast cancer	1.25e-05	7.47e-05	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—breast cancer	1.24e-05	7.46e-05	CcSEcCtD
Thalidomide—Pain—Capecitabine—breast cancer	1.24e-05	7.44e-05	CcSEcCtD
Thalidomide—Constipation—Capecitabine—breast cancer	1.24e-05	7.44e-05	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—breast cancer	1.24e-05	7.43e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Docetaxel—breast cancer	1.23e-05	7.41e-05	CcSEcCtD
Thalidomide—Nausea—Fluorouracil—breast cancer	1.23e-05	7.4e-05	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—breast cancer	1.23e-05	7.38e-05	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—breast cancer	1.23e-05	7.36e-05	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—breast cancer	1.23e-05	7.36e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Docetaxel—breast cancer	1.23e-05	7.35e-05	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—breast cancer	1.22e-05	7.33e-05	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—breast cancer	1.22e-05	7.33e-05	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—breast cancer	1.22e-05	7.32e-05	CcSEcCtD
Thalidomide—Tension—Epirubicin—breast cancer	1.21e-05	7.29e-05	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—breast cancer	1.21e-05	7.27e-05	CcSEcCtD
Thalidomide—Diarrhoea—Paclitaxel—breast cancer	1.21e-05	7.25e-05	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—breast cancer	1.2e-05	7.21e-05	CcSEcCtD
Thalidomide—Back pain—Epirubicin—breast cancer	1.2e-05	7.18e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Capecitabine—breast cancer	1.2e-05	7.17e-05	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—breast cancer	1.19e-05	7.16e-05	CcSEcCtD
Thalidomide—Malaise—Methotrexate—breast cancer	1.19e-05	7.16e-05	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—breast cancer	1.19e-05	7.14e-05	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—breast cancer	1.19e-05	7.13e-05	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—breast cancer	1.19e-05	7.13e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Capecitabine—breast cancer	1.19e-05	7.11e-05	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—breast cancer	1.19e-05	7.11e-05	CcSEcCtD
Thalidomide—Abdominal pain—Docetaxel—breast cancer	1.18e-05	7.1e-05	CcSEcCtD
Thalidomide—Body temperature increased—Docetaxel—breast cancer	1.18e-05	7.1e-05	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—breast cancer	1.18e-05	7.1e-05	CcSEcCtD
Thalidomide—Chills—Doxorubicin—breast cancer	1.18e-05	7.08e-05	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—breast cancer	1.18e-05	7.05e-05	CcSEcCtD
Thalidomide—Dizziness—Paclitaxel—breast cancer	1.17e-05	7.01e-05	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—breast cancer	1.17e-05	7e-05	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—breast cancer	1.16e-05	6.98e-05	CcSEcCtD
Thalidomide—Cough—Methotrexate—breast cancer	1.15e-05	6.93e-05	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—breast cancer	1.15e-05	6.92e-05	CcSEcCtD
Thalidomide—Urticaria—Capecitabine—breast cancer	1.15e-05	6.91e-05	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—breast cancer	1.15e-05	6.89e-05	CcSEcCtD
Thalidomide—Abdominal pain—Capecitabine—breast cancer	1.15e-05	6.88e-05	CcSEcCtD
Thalidomide—Body temperature increased—Capecitabine—breast cancer	1.15e-05	6.88e-05	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—breast cancer	1.15e-05	6.88e-05	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—breast cancer	1.15e-05	6.87e-05	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—breast cancer	1.14e-05	6.86e-05	CcSEcCtD
Thalidomide—Agitation—Epirubicin—breast cancer	1.14e-05	6.82e-05	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—breast cancer	1.13e-05	6.77e-05	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—breast cancer	1.13e-05	6.76e-05	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—breast cancer	1.13e-05	6.76e-05	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—breast cancer	1.13e-05	6.76e-05	CcSEcCtD
Thalidomide—Tension—Doxorubicin—breast cancer	1.12e-05	6.74e-05	CcSEcCtD
Thalidomide—Vomiting—Paclitaxel—breast cancer	1.12e-05	6.74e-05	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—breast cancer	1.12e-05	6.73e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.12e-05	6.71e-05	CcSEcCtD
Thalidomide—Malaise—Epirubicin—breast cancer	1.12e-05	6.7e-05	CcSEcCtD
Thalidomide—Rash—Paclitaxel—breast cancer	1.11e-05	6.68e-05	CcSEcCtD
Thalidomide—Dermatitis—Paclitaxel—breast cancer	1.11e-05	6.68e-05	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—breast cancer	1.11e-05	6.68e-05	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—breast cancer	1.11e-05	6.67e-05	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—breast cancer	1.11e-05	6.67e-05	CcSEcCtD
Thalidomide—Syncope—Epirubicin—breast cancer	1.11e-05	6.66e-05	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—breast cancer	1.11e-05	6.65e-05	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—breast cancer	1.11e-05	6.65e-05	CcSEcCtD
Thalidomide—Headache—Paclitaxel—breast cancer	1.11e-05	6.64e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Docetaxel—breast cancer	1.1e-05	6.62e-05	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—breast cancer	1.1e-05	6.61e-05	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—breast cancer	1.09e-05	6.56e-05	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—breast cancer	1.09e-05	6.53e-05	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—breast cancer	1.09e-05	6.53e-05	CcSEcCtD
Thalidomide—Cough—Epirubicin—breast cancer	1.08e-05	6.48e-05	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—breast cancer	1.08e-05	6.48e-05	CcSEcCtD
Thalidomide—Asthenia—Docetaxel—breast cancer	1.07e-05	6.45e-05	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—breast cancer	1.07e-05	6.43e-05	CcSEcCtD
Thalidomide—Infection—Methotrexate—breast cancer	1.07e-05	6.43e-05	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—breast cancer	1.07e-05	6.41e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Capecitabine—breast cancer	1.07e-05	6.41e-05	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—breast cancer	1.06e-05	6.38e-05	CcSEcCtD
Thalidomide—Pruritus—Docetaxel—breast cancer	1.06e-05	6.36e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—breast cancer	1.06e-05	6.35e-05	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—breast cancer	1.06e-05	6.35e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—breast cancer	1.06e-05	6.34e-05	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—breast cancer	1.05e-05	6.32e-05	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—breast cancer	1.05e-05	6.32e-05	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—breast cancer	1.05e-05	6.32e-05	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—breast cancer	1.05e-05	6.31e-05	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—breast cancer	1.05e-05	6.3e-05	CcSEcCtD
Thalidomide—Nausea—Paclitaxel—breast cancer	1.05e-05	6.3e-05	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—breast cancer	1.05e-05	6.29e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.05e-05	6.28e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—breast cancer	1.04e-05	6.26e-05	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—breast cancer	1.04e-05	6.25e-05	CcSEcCtD
Thalidomide—Asthenia—Capecitabine—breast cancer	1.04e-05	6.24e-05	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—breast cancer	1.03e-05	6.2e-05	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—breast cancer	1.03e-05	6.18e-05	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—breast cancer	1.03e-05	6.17e-05	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—breast cancer	1.03e-05	6.17e-05	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—breast cancer	1.03e-05	6.16e-05	CcSEcCtD
Thalidomide—Pruritus—Capecitabine—breast cancer	1.03e-05	6.16e-05	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—breast cancer	1.03e-05	6.15e-05	CcSEcCtD
Thalidomide—Diarrhoea—Docetaxel—breast cancer	1.03e-05	6.15e-05	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—breast cancer	1.02e-05	6.11e-05	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—breast cancer	1.01e-05	6.07e-05	CcSEcCtD
Thalidomide—Oedema—Epirubicin—breast cancer	1.01e-05	6.06e-05	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—breast cancer	1.01e-05	6.05e-05	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—breast cancer	1.01e-05	6.04e-05	CcSEcCtD
Thalidomide—Infection—Epirubicin—breast cancer	1e-05	6.02e-05	CcSEcCtD
Thalidomide—Cough—Doxorubicin—breast cancer	1e-05	6e-05	CcSEcCtD
Thalidomide—Shock—Epirubicin—breast cancer	9.94e-06	5.96e-05	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—breast cancer	9.93e-06	5.95e-05	CcSEcCtD
Thalidomide—Diarrhoea—Capecitabine—breast cancer	9.92e-06	5.95e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—breast cancer	9.91e-06	5.94e-05	CcSEcCtD
Thalidomide—Dizziness—Docetaxel—breast cancer	9.91e-06	5.94e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—breast cancer	9.89e-06	5.93e-05	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—breast cancer	9.89e-06	5.93e-05	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—breast cancer	9.86e-06	5.92e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—breast cancer	9.84e-06	5.9e-05	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—breast cancer	9.82e-06	5.89e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—breast cancer	9.77e-06	5.86e-05	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—breast cancer	9.77e-06	5.86e-05	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—breast cancer	9.75e-06	5.85e-05	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—breast cancer	9.75e-06	5.85e-05	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—breast cancer	9.75e-06	5.85e-05	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—breast cancer	9.72e-06	5.83e-05	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—breast cancer	9.7e-06	5.82e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	9.69e-06	5.81e-05	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—breast cancer	9.64e-06	5.78e-05	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—breast cancer	9.63e-06	5.78e-05	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—breast cancer	9.63e-06	5.77e-05	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—breast cancer	9.6e-06	5.76e-05	CcSEcCtD
Thalidomide—Dizziness—Capecitabine—breast cancer	9.59e-06	5.75e-05	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—breast cancer	9.54e-06	5.72e-05	CcSEcCtD
Thalidomide—Vomiting—Docetaxel—breast cancer	9.53e-06	5.71e-05	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—breast cancer	9.5e-06	5.7e-05	CcSEcCtD
Thalidomide—Rash—Docetaxel—breast cancer	9.45e-06	5.67e-05	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—breast cancer	9.44e-06	5.66e-05	CcSEcCtD
Thalidomide—Dermatitis—Docetaxel—breast cancer	9.44e-06	5.66e-05	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—breast cancer	9.43e-06	5.65e-05	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—breast cancer	9.39e-06	5.63e-05	CcSEcCtD
Thalidomide—Headache—Docetaxel—breast cancer	9.39e-06	5.63e-05	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—breast cancer	9.35e-06	5.61e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—breast cancer	9.32e-06	5.59e-05	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—breast cancer	9.31e-06	5.58e-05	CcSEcCtD
Thalidomide—Infection—Doxorubicin—breast cancer	9.29e-06	5.57e-05	CcSEcCtD
Thalidomide—Pain—Methotrexate—breast cancer	9.23e-06	5.54e-05	CcSEcCtD
Thalidomide—Vomiting—Capecitabine—breast cancer	9.22e-06	5.53e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—breast cancer	9.21e-06	5.52e-05	CcSEcCtD
Thalidomide—Shock—Doxorubicin—breast cancer	9.2e-06	5.52e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—breast cancer	9.17e-06	5.5e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—breast cancer	9.15e-06	5.49e-05	CcSEcCtD
Thalidomide—Rash—Capecitabine—breast cancer	9.15e-06	5.49e-05	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—breast cancer	9.14e-06	5.48e-05	CcSEcCtD
Thalidomide—Dermatitis—Capecitabine—breast cancer	9.14e-06	5.48e-05	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—breast cancer	9.13e-06	5.47e-05	CcSEcCtD
Thalidomide—Headache—Capecitabine—breast cancer	9.09e-06	5.45e-05	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—breast cancer	9.08e-06	5.45e-05	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—breast cancer	9.07e-06	5.44e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—breast cancer	9.04e-06	5.42e-05	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—breast cancer	9.01e-06	5.4e-05	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—breast cancer	8.98e-06	5.39e-05	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—breast cancer	8.91e-06	5.35e-05	CcSEcCtD
Thalidomide—Nausea—Docetaxel—breast cancer	8.9e-06	5.34e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—breast cancer	8.9e-06	5.34e-05	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—breast cancer	8.89e-06	5.34e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—breast cancer	8.83e-06	5.3e-05	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—breast cancer	8.78e-06	5.27e-05	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—breast cancer	8.74e-06	5.24e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—breast cancer	8.72e-06	5.23e-05	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—breast cancer	8.71e-06	5.23e-05	CcSEcCtD
Thalidomide—Constipation—Epirubicin—breast cancer	8.64e-06	5.18e-05	CcSEcCtD
Thalidomide—Pain—Epirubicin—breast cancer	8.64e-06	5.18e-05	CcSEcCtD
Thalidomide—Nausea—Capecitabine—breast cancer	8.62e-06	5.17e-05	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—breast cancer	8.58e-06	5.15e-05	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—breast cancer	8.54e-06	5.12e-05	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—breast cancer	8.54e-06	5.12e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—breast cancer	8.52e-06	5.11e-05	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—breast cancer	8.46e-06	5.07e-05	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—breast cancer	8.4e-06	5.04e-05	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—breast cancer	8.34e-06	5e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—breast cancer	8.33e-06	4.99e-05	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—breast cancer	8.31e-06	4.99e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—breast cancer	8.26e-06	4.96e-05	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—breast cancer	8.23e-06	4.94e-05	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—breast cancer	8.13e-06	4.88e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—breast cancer	8.07e-06	4.84e-05	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—breast cancer	8.06e-06	4.84e-05	CcSEcCtD
Thalidomide—Urticaria—Epirubicin—breast cancer	8.03e-06	4.82e-05	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—breast cancer	8e-06	4.8e-05	CcSEcCtD
Thalidomide—Pain—Doxorubicin—breast cancer	8e-06	4.8e-05	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—breast cancer	7.99e-06	4.79e-05	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—breast cancer	7.99e-06	4.79e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—breast cancer	7.96e-06	4.77e-05	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—breast cancer	7.75e-06	4.65e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—breast cancer	7.7e-06	4.62e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—breast cancer	7.65e-06	4.59e-05	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—breast cancer	7.64e-06	4.58e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Epirubicin—breast cancer	7.44e-06	4.47e-05	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—breast cancer	7.43e-06	4.46e-05	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—breast cancer	7.39e-06	4.43e-05	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—breast cancer	7.39e-06	4.43e-05	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—breast cancer	7.39e-06	4.43e-05	CcSEcCtD
Thalidomide—Asthenia—Epirubicin—breast cancer	7.25e-06	4.35e-05	CcSEcCtD
Thalidomide—Pruritus—Epirubicin—breast cancer	7.15e-06	4.29e-05	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—breast cancer	7.14e-06	4.28e-05	CcSEcCtD
Thalidomide—Diarrhoea—Epirubicin—breast cancer	6.91e-06	4.15e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—breast cancer	6.89e-06	4.13e-05	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—breast cancer	6.87e-06	4.12e-05	CcSEcCtD
Thalidomide—Rash—Methotrexate—breast cancer	6.81e-06	4.08e-05	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—breast cancer	6.8e-06	4.08e-05	CcSEcCtD
Thalidomide—Headache—Methotrexate—breast cancer	6.76e-06	4.06e-05	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—breast cancer	6.71e-06	4.02e-05	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—breast cancer	6.68e-06	4.01e-05	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—breast cancer	6.61e-06	3.97e-05	CcSEcCtD
Thalidomide—Vomiting—Epirubicin—breast cancer	6.42e-06	3.85e-05	CcSEcCtD
Thalidomide—Nausea—Methotrexate—breast cancer	6.41e-06	3.85e-05	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—breast cancer	6.4e-06	3.84e-05	CcSEcCtD
Thalidomide—Rash—Epirubicin—breast cancer	6.37e-06	3.82e-05	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—breast cancer	6.37e-06	3.82e-05	CcSEcCtD
Thalidomide—Headache—Epirubicin—breast cancer	6.33e-06	3.8e-05	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—breast cancer	6.18e-06	3.71e-05	CcSEcCtD
Thalidomide—Nausea—Epirubicin—breast cancer	6e-06	3.6e-05	CcSEcCtD
Thalidomide—Vomiting—Doxorubicin—breast cancer	5.94e-06	3.57e-05	CcSEcCtD
Thalidomide—Rash—Doxorubicin—breast cancer	5.9e-06	3.54e-05	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—breast cancer	5.89e-06	3.53e-05	CcSEcCtD
Thalidomide—Headache—Doxorubicin—breast cancer	5.86e-06	3.51e-05	CcSEcCtD
Thalidomide—Nausea—Doxorubicin—breast cancer	5.55e-06	3.33e-05	CcSEcCtD
Thalidomide—CYP2C19—Metabolism—HSP90AA1—breast cancer	1.28e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A1—breast cancer	1.28e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ACHE—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NCOR1—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G4A—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ERCC2—breast cancer	1.27e-06	1.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—breast cancer	1.27e-06	1.01e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ERCC2—breast cancer	1.27e-06	1.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—breast cancer	1.26e-06	1.01e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—breast cancer	1.26e-06	1.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—breast cancer	1.26e-06	1.01e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—breast cancer	1.26e-06	1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGF—breast cancer	1.26e-06	1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—breast cancer	1.25e-06	1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—breast cancer	1.25e-06	9.99e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NCOA1—breast cancer	1.24e-06	9.92e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NQO1—breast cancer	1.24e-06	9.89e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A1—breast cancer	1.24e-06	9.89e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—breast cancer	1.23e-06	9.82e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—breast cancer	1.23e-06	9.8e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—STK11—breast cancer	1.23e-06	9.78e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—breast cancer	1.23e-06	9.78e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—breast cancer	1.22e-06	9.77e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—breast cancer	1.22e-06	9.73e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—breast cancer	1.22e-06	9.73e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.21e-06	9.69e-06	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—breast cancer	1.21e-06	9.65e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP3A4—breast cancer	1.21e-06	9.65e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP17A1—breast cancer	1.21e-06	9.63e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.2e-06	9.6e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—breast cancer	1.2e-06	9.57e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ERCC2—breast cancer	1.2e-06	9.56e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—breast cancer	1.2e-06	9.55e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—breast cancer	1.2e-06	9.54e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—breast cancer	1.19e-06	9.53e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO1—breast cancer	1.19e-06	9.53e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS1—breast cancer	1.19e-06	9.53e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—breast cancer	1.19e-06	9.53e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—breast cancer	1.19e-06	9.51e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—breast cancer	1.19e-06	9.5e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	1.19e-06	9.5e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1B1—breast cancer	1.19e-06	9.49e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—breast cancer	1.19e-06	9.48e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CD—breast cancer	1.18e-06	9.42e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	1.18e-06	9.38e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2D6—breast cancer	1.17e-06	9.35e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAV1—breast cancer	1.17e-06	9.33e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HSP90AA1—breast cancer	1.17e-06	9.3e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—breast cancer	1.16e-06	9.29e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT2—breast cancer	1.16e-06	9.29e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—breast cancer	1.16e-06	9.27e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SRC—breast cancer	1.16e-06	9.26e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.15e-06	9.18e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NCOA2—breast cancer	1.15e-06	9.18e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—breast cancer	1.15e-06	9.16e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—COMT—breast cancer	1.14e-06	9.09e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—breast cancer	1.13e-06	9.05e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NCOA1—breast cancer	1.13e-06	9.05e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—breast cancer	1.13e-06	9.02e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—breast cancer	1.13e-06	8.98e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—breast cancer	1.12e-06	8.93e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CD—breast cancer	1.12e-06	8.93e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—breast cancer	1.12e-06	8.93e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—STK11—breast cancer	1.12e-06	8.92e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—breast cancer	1.12e-06	8.92e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.12e-06	8.92e-06	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—breast cancer	1.12e-06	8.91e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ITPR1—breast cancer	1.12e-06	8.9e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FASN—breast cancer	1.12e-06	8.9e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—breast cancer	1.11e-06	8.89e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BCHE—breast cancer	1.11e-06	8.86e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—breast cancer	1.11e-06	8.84e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—breast cancer	1.11e-06	8.83e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SRC—breast cancer	1.1e-06	8.79e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAV1—breast cancer	1.1e-06	8.79e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAV1—breast cancer	1.1e-06	8.77e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC5A5—breast cancer	1.1e-06	8.75e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—breast cancer	1.07e-06	8.57e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—breast cancer	1.07e-06	8.56e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK3—breast cancer	1.07e-06	8.54e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—breast cancer	1.07e-06	8.5e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—breast cancer	1.06e-06	8.48e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—breast cancer	1.06e-06	8.46e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NQO1—breast cancer	1.06e-06	8.45e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A1—breast cancer	1.06e-06	8.45e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—breast cancer	1.06e-06	8.45e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—breast cancer	1.06e-06	8.43e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMS—breast cancer	1.05e-06	8.41e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.05e-06	8.37e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NCOR1—breast cancer	1.04e-06	8.32e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G4A—breast cancer	1.04e-06	8.32e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—breast cancer	1.04e-06	8.32e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—breast cancer	1.04e-06	8.3e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COMT—breast cancer	1.04e-06	8.29e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAV1—breast cancer	1.04e-06	8.28e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—breast cancer	1.04e-06	8.28e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.04e-06	8.28e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—breast cancer	1.03e-06	8.25e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP3A4—breast cancer	1.03e-06	8.24e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CB—breast cancer	1.03e-06	8.21e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.03e-06	8.2e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—breast cancer	1.02e-06	8.14e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—breast cancer	1.02e-06	8.13e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—breast cancer	1.02e-06	8.12e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ITPR1—breast cancer	1.02e-06	8.12e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1B1—breast cancer	1.02e-06	8.11e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK3—breast cancer	1.02e-06	8.1e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—breast cancer	1e-06	8e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MDM2—breast cancer	1e-06	8e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—breast cancer	1e-06	7.99e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RAF1—breast cancer	9.99e-07	7.97e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—breast cancer	9.98e-07	7.96e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HSP90AA1—breast cancer	9.96e-07	7.95e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	9.92e-07	7.91e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A1—breast cancer	9.88e-07	7.88e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—breast cancer	9.88e-07	7.88e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—breast cancer	9.87e-07	7.88e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—breast cancer	9.85e-07	7.86e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ERCC2—breast cancer	9.8e-07	7.82e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—breast cancer	9.79e-07	7.81e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—breast cancer	9.78e-07	7.8e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTOR—breast cancer	9.75e-07	7.78e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CB—breast cancer	9.75e-07	7.78e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—breast cancer	9.73e-07	7.77e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NCOA1—breast cancer	9.69e-07	7.73e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—breast cancer	9.66e-07	7.71e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—breast cancer	9.61e-07	7.67e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMS—breast cancer	9.61e-07	7.67e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—STK11—breast cancer	9.55e-07	7.62e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—breast cancer	9.55e-07	7.62e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NCOR1—breast cancer	9.5e-07	7.58e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G4A—breast cancer	9.5e-07	7.58e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—breast cancer	9.5e-07	7.58e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—breast cancer	9.46e-07	7.55e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CD—breast cancer	9.37e-07	7.47e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—breast cancer	9.25e-07	7.38e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—breast cancer	9.21e-07	7.35e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—breast cancer	9.15e-07	7.3e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—breast cancer	9.12e-07	7.28e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—breast cancer	9.1e-07	7.26e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A1—breast cancer	9.01e-07	7.19e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	8.97e-07	7.15e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ERCC2—breast cancer	8.93e-07	7.13e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—breast cancer	8.89e-07	7.09e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COMT—breast cancer	8.88e-07	7.08e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—breast cancer	8.85e-07	7.06e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—breast cancer	8.84e-07	7.05e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—breast cancer	8.83e-07	7.05e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CD—breast cancer	8.82e-07	7.04e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CD—breast cancer	8.8e-07	7.02e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—breast cancer	8.72e-07	6.95e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—breast cancer	8.7e-07	6.95e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ITPR1—breast cancer	8.7e-07	6.94e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—breast cancer	8.69e-07	6.93e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—breast cancer	8.64e-07	6.9e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—breast cancer	8.54e-07	6.82e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAV1—breast cancer	8.5e-07	6.78e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—breast cancer	8.44e-07	6.74e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—breast cancer	8.42e-07	6.72e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—breast cancer	8.4e-07	6.7e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—breast cancer	8.38e-07	6.69e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—breast cancer	8.37e-07	6.67e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—breast cancer	8.33e-07	6.64e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CD—breast cancer	8.31e-07	6.63e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—breast cancer	8.31e-07	6.63e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMS—breast cancer	8.22e-07	6.56e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—breast cancer	8.21e-07	6.55e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—breast cancer	8.17e-07	6.52e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CB—breast cancer	8.16e-07	6.52e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G4A—breast cancer	8.12e-07	6.48e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—breast cancer	8.12e-07	6.48e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NCOR1—breast cancer	8.12e-07	6.48e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	8.12e-07	6.48e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—breast cancer	8.11e-07	6.47e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—breast cancer	7.85e-07	6.26e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—breast cancer	7.82e-07	6.24e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SRC—breast cancer	7.81e-07	6.23e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—breast cancer	7.78e-07	6.21e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—breast cancer	7.75e-07	6.19e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAV1—breast cancer	7.75e-07	6.18e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—breast cancer	7.74e-07	6.18e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1A1—breast cancer	7.7e-07	6.14e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CB—breast cancer	7.69e-07	6.13e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CB—breast cancer	7.67e-07	6.12e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ERCC2—breast cancer	7.64e-07	6.09e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—breast cancer	7.62e-07	6.08e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—breast cancer	7.6e-07	6.06e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—breast cancer	7.53e-07	6.01e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—breast cancer	7.42e-07	5.92e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	7.4e-07	5.91e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CB—breast cancer	7.25e-07	5.78e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—breast cancer	7.22e-07	5.76e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK3—breast cancer	7.2e-07	5.74e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—breast cancer	7.18e-07	5.73e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—breast cancer	7.18e-07	5.73e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—breast cancer	7.06e-07	5.63e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—breast cancer	7.06e-07	5.63e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—breast cancer	7e-07	5.59e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—breast cancer	6.98e-07	5.57e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—breast cancer	6.85e-07	5.46e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—breast cancer	6.85e-07	5.46e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CD—breast cancer	6.8e-07	5.43e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—breast cancer	6.72e-07	5.36e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—breast cancer	6.64e-07	5.3e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—breast cancer	6.63e-07	5.29e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAV1—breast cancer	6.62e-07	5.28e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—breast cancer	6.47e-07	5.16e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—breast cancer	6.42e-07	5.13e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.32e-07	5.05e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—breast cancer	6.27e-07	5e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—breast cancer	6.26e-07	5e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CD—breast cancer	6.2e-07	4.95e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—breast cancer	6.12e-07	4.89e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—breast cancer	6.03e-07	4.81e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—breast cancer	5.94e-07	4.74e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CB—breast cancer	5.93e-07	4.73e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—breast cancer	5.88e-07	4.69e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—breast cancer	5.86e-07	4.67e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—breast cancer	5.5e-07	4.39e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CB—breast cancer	5.41e-07	4.31e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—breast cancer	5.36e-07	4.27e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CD—breast cancer	5.3e-07	4.23e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—breast cancer	5.26e-07	4.2e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—breast cancer	5.23e-07	4.18e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—breast cancer	5.12e-07	4.09e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—breast cancer	5.12e-07	4.09e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—breast cancer	5.01e-07	3.99e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—breast cancer	4.98e-07	3.97e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—breast cancer	4.86e-07	3.87e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—breast cancer	4.69e-07	3.74e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—breast cancer	4.68e-07	3.73e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—breast cancer	4.67e-07	3.73e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CB—breast cancer	4.62e-07	3.69e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—breast cancer	4.58e-07	3.65e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—breast cancer	4.42e-07	3.52e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—breast cancer	4.07e-07	3.24e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—breast cancer	3.99e-07	3.19e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—breast cancer	3.83e-07	3.05e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—breast cancer	3.82e-07	3.05e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—breast cancer	3.61e-07	2.88e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—breast cancer	3.61e-07	2.88e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—breast cancer	3.3e-07	2.63e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—breast cancer	2.95e-07	2.36e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—breast cancer	2.82e-07	2.25e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—breast cancer	2.69e-07	2.15e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—breast cancer	2.3e-07	1.84e-06	CbGpPWpGaD
